Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma 1Peritoneal Metastases From Gastric Cancer 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1Epstein-Barr Virus Infections 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 1cabozantinib 1apatinib 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Adenoid Cystic × apatinib × Clear all
NCT04119453 2024-06-24

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Elevar Therapeutics

Phase 2 Terminated
80 enrolled

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡